Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract
Study sponsor: Enanta Pharmaceuticals, Inc · ENTA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-31Actual
Enrollment · participants9Actual
Source updated2024-08-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.